Adrenomedullin and diabetes mellitus

Eva Ruzicska, Miklos Toth, Z. Tulassay, A. Somogyi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Adrenomedullin (AM) is a novel 52 amino acid peptide hormone, originally isolated from human pheochromocytoma. AM acts as a local autocrine and/or paracrine vasoactive hormone and has vasodilator and blood pressure lowering properties. AM as a vasodilative molecule protects the vascular wall but its exact role is still uncertain. AM is considered to play an important endocrine role in various tissues in maintaining electrolyte and fluid homeostasis. Its plasma concentration in healthy conditions. is low. In hypertension, chronic renal failure and congestive heart failure its plasma concentration increases in a parallel manner with the severity of the disease. It is assumed that this peptide plays an important role in physiological and pathological conditions compensating the effects of vasoconstrictive molecules. Investigations have proven that in diabetic angiopathies the levels and production of vasoconstrictive factors and AM are increased, while other relaxing substances such as nitric oxide (NO) are decreased. It is still uncertain whether the increased release of AM is a compensatory mechanism or a coincidental event. Although the precise role of AM in the pathogenesis of diabetic complications is still to be elucidated, the altered concentration of AM in diabetes could indicate a certain interaction between AM induction and vascular function. Hence, the induction of vascular AM can be a new target of therapeutic approach to diabetic complications.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalDiabetes/Metabolism Research and Reviews
Volume17
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Adrenomedullin
Medical problems
Diabetes Mellitus
Blood Vessels
Diabetes Complications
Plasmas
Diabetic Angiopathies
Molecules
Peptide Hormones
Blood pressure
Pheochromocytoma
Vasodilator Agents
Electrolytes
Chronic Kidney Failure
Nitric Oxide
Homeostasis
Heart Failure
Hormones
Tissue
Blood Pressure

Keywords

  • Adrenomedullin
  • Atherosclerosis
  • Diabetes mellitus
  • Endothelial dysfunction
  • Vasoactive peptides

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Adrenomedullin and diabetes mellitus. / Ruzicska, Eva; Toth, Miklos; Tulassay, Z.; Somogyi, A.

In: Diabetes/Metabolism Research and Reviews, Vol. 17, No. 5, 2001, p. 321-329.

Research output: Contribution to journalArticle

Ruzicska, Eva ; Toth, Miklos ; Tulassay, Z. ; Somogyi, A. / Adrenomedullin and diabetes mellitus. In: Diabetes/Metabolism Research and Reviews. 2001 ; Vol. 17, No. 5. pp. 321-329.
@article{8ac7a53a27d94b73bc91169c9670b020,
title = "Adrenomedullin and diabetes mellitus",
abstract = "Adrenomedullin (AM) is a novel 52 amino acid peptide hormone, originally isolated from human pheochromocytoma. AM acts as a local autocrine and/or paracrine vasoactive hormone and has vasodilator and blood pressure lowering properties. AM as a vasodilative molecule protects the vascular wall but its exact role is still uncertain. AM is considered to play an important endocrine role in various tissues in maintaining electrolyte and fluid homeostasis. Its plasma concentration in healthy conditions. is low. In hypertension, chronic renal failure and congestive heart failure its plasma concentration increases in a parallel manner with the severity of the disease. It is assumed that this peptide plays an important role in physiological and pathological conditions compensating the effects of vasoconstrictive molecules. Investigations have proven that in diabetic angiopathies the levels and production of vasoconstrictive factors and AM are increased, while other relaxing substances such as nitric oxide (NO) are decreased. It is still uncertain whether the increased release of AM is a compensatory mechanism or a coincidental event. Although the precise role of AM in the pathogenesis of diabetic complications is still to be elucidated, the altered concentration of AM in diabetes could indicate a certain interaction between AM induction and vascular function. Hence, the induction of vascular AM can be a new target of therapeutic approach to diabetic complications.",
keywords = "Adrenomedullin, Atherosclerosis, Diabetes mellitus, Endothelial dysfunction, Vasoactive peptides",
author = "Eva Ruzicska and Miklos Toth and Z. Tulassay and A. Somogyi",
year = "2001",
doi = "10.1002/dmrr.223",
language = "English",
volume = "17",
pages = "321--329",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Adrenomedullin and diabetes mellitus

AU - Ruzicska, Eva

AU - Toth, Miklos

AU - Tulassay, Z.

AU - Somogyi, A.

PY - 2001

Y1 - 2001

N2 - Adrenomedullin (AM) is a novel 52 amino acid peptide hormone, originally isolated from human pheochromocytoma. AM acts as a local autocrine and/or paracrine vasoactive hormone and has vasodilator and blood pressure lowering properties. AM as a vasodilative molecule protects the vascular wall but its exact role is still uncertain. AM is considered to play an important endocrine role in various tissues in maintaining electrolyte and fluid homeostasis. Its plasma concentration in healthy conditions. is low. In hypertension, chronic renal failure and congestive heart failure its plasma concentration increases in a parallel manner with the severity of the disease. It is assumed that this peptide plays an important role in physiological and pathological conditions compensating the effects of vasoconstrictive molecules. Investigations have proven that in diabetic angiopathies the levels and production of vasoconstrictive factors and AM are increased, while other relaxing substances such as nitric oxide (NO) are decreased. It is still uncertain whether the increased release of AM is a compensatory mechanism or a coincidental event. Although the precise role of AM in the pathogenesis of diabetic complications is still to be elucidated, the altered concentration of AM in diabetes could indicate a certain interaction between AM induction and vascular function. Hence, the induction of vascular AM can be a new target of therapeutic approach to diabetic complications.

AB - Adrenomedullin (AM) is a novel 52 amino acid peptide hormone, originally isolated from human pheochromocytoma. AM acts as a local autocrine and/or paracrine vasoactive hormone and has vasodilator and blood pressure lowering properties. AM as a vasodilative molecule protects the vascular wall but its exact role is still uncertain. AM is considered to play an important endocrine role in various tissues in maintaining electrolyte and fluid homeostasis. Its plasma concentration in healthy conditions. is low. In hypertension, chronic renal failure and congestive heart failure its plasma concentration increases in a parallel manner with the severity of the disease. It is assumed that this peptide plays an important role in physiological and pathological conditions compensating the effects of vasoconstrictive molecules. Investigations have proven that in diabetic angiopathies the levels and production of vasoconstrictive factors and AM are increased, while other relaxing substances such as nitric oxide (NO) are decreased. It is still uncertain whether the increased release of AM is a compensatory mechanism or a coincidental event. Although the precise role of AM in the pathogenesis of diabetic complications is still to be elucidated, the altered concentration of AM in diabetes could indicate a certain interaction between AM induction and vascular function. Hence, the induction of vascular AM can be a new target of therapeutic approach to diabetic complications.

KW - Adrenomedullin

KW - Atherosclerosis

KW - Diabetes mellitus

KW - Endothelial dysfunction

KW - Vasoactive peptides

UR - http://www.scopus.com/inward/record.url?scp=0034761632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034761632&partnerID=8YFLogxK

U2 - 10.1002/dmrr.223

DO - 10.1002/dmrr.223

M3 - Article

C2 - 11747138

AN - SCOPUS:0034761632

VL - 17

SP - 321

EP - 329

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 5

ER -